FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134607788> ?p ?o ?g. }

• W2134607788 endingPage "167" @default.
• W2134607788 startingPage "160" @default.
• W2134607788 abstract "Objective In the present review article we summarize available clinical and preclinical evidence, if modulation of the subthalamic nucleus (STN) could be a target for neuroprotection in Parkinson’s disease (PD). Background Chronic deep brain stimulation (DBS) of the STN has emerged as a powerful therapeutic alternative for the treatment of PD, ensuring stable symptom control for up to five years despite the progressive nature PD. Materials and Methods Comparative review of literature in PuBMed available up to December 2008. Results The assessment of neuroprotection has been proven difficult in the clinical situation, as medical or surgical therapeutic options that improve PD symptoms could be erroneously considered to be neuroprotective because of the difficulty of differentiating between symptomatic effects and potential neuromodulative disease-related effects of various treatment options applied in PD. The methodological limitations of clinical trials underline the importance of putative neuroprotective compounds to be tested in clinically driven preclinical studies. Thus, animal models, mimicking progressive nigrostriatal cell death, are indispensable to further advance the important issue of neuroprotection or neuromodulation following DBS. Conclusion Clear clinical evidence for STN-DBS-related neuroprotection in PD is missing. However, numerous preclinical studies show (and are discussed) that silencing of the STN via lesion or DBS may exert neuromodulative effects on nigral dopamine neurons. In the present review article we summarize available clinical and preclinical evidence, if modulation of the subthalamic nucleus (STN) could be a target for neuroprotection in Parkinson’s disease (PD). Chronic deep brain stimulation (DBS) of the STN has emerged as a powerful therapeutic alternative for the treatment of PD, ensuring stable symptom control for up to five years despite the progressive nature PD. Comparative review of literature in PuBMed available up to December 2008. The assessment of neuroprotection has been proven difficult in the clinical situation, as medical or surgical therapeutic options that improve PD symptoms could be erroneously considered to be neuroprotective because of the difficulty of differentiating between symptomatic effects and potential neuromodulative disease-related effects of various treatment options applied in PD. The methodological limitations of clinical trials underline the importance of putative neuroprotective compounds to be tested in clinically driven preclinical studies. Thus, animal models, mimicking progressive nigrostriatal cell death, are indispensable to further advance the important issue of neuroprotection or neuromodulation following DBS. Clear clinical evidence for STN-DBS-related neuroprotection in PD is missing. However, numerous preclinical studies show (and are discussed) that silencing of the STN via lesion or DBS may exert neuromodulative effects on nigral dopamine neurons." @default.
• W2134607788 created "2016-06-24" @default.
• W2134607788 creator A5067081068 @default.
• W2134607788 creator A5083610914 @default.
• W2134607788 date "2010-07-01" @default.
• W2134607788 modified "2023-10-01" @default.
• W2134607788 title "The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection-Myth or Reality?" @default.
• W2134607788 cites W140137023 @default.
• W2134607788 cites W1544052774 @default.
• W2134607788 cites W1768450208 @default.
• W2134607788 cites W1947356649 @default.
• W2134607788 cites W1964711817 @default.
• W2134607788 cites W1968893317 @default.
• W2134607788 cites W1975496798 @default.
• W2134607788 cites W1980467455 @default.
• W2134607788 cites W1983137640 @default.
• W2134607788 cites W1983452416 @default.
• W2134607788 cites W1997887984 @default.
• W2134607788 cites W2001867045 @default.
• W2134607788 cites W2003551938 @default.
• W2134607788 cites W2005143175 @default.
• W2134607788 cites W2005646823 @default.
• W2134607788 cites W2008123743 @default.
• W2134607788 cites W2014122802 @default.
• W2134607788 cites W2020078576 @default.
• W2134607788 cites W2022426651 @default.
• W2134607788 cites W2023098845 @default.
• W2134607788 cites W2023890073 @default.
• W2134607788 cites W2024426916 @default.
• W2134607788 cites W2027094797 @default.
• W2134607788 cites W2027559291 @default.
• W2134607788 cites W2045434558 @default.
• W2134607788 cites W2046057346 @default.
• W2134607788 cites W2051004303 @default.
• W2134607788 cites W2061079288 @default.
• W2134607788 cites W2084101474 @default.
• W2134607788 cites W2084910998 @default.
• W2134607788 cites W2088037244 @default.
• W2134607788 cites W2088189017 @default.
• W2134607788 cites W2092481216 @default.
• W2134607788 cites W2095270577 @default.
• W2134607788 cites W2096892963 @default.
• W2134607788 cites W2111845306 @default.
• W2134607788 cites W2116616124 @default.
• W2134607788 cites W2118868654 @default.
• W2134607788 cites W2119717135 @default.
• W2134607788 cites W2124227727 @default.
• W2134607788 cites W2124550832 @default.
• W2134607788 cites W2131671532 @default.
• W2134607788 cites W2135269664 @default.
• W2134607788 cites W2149476088 @default.
• W2134607788 cites W2152727843 @default.
• W2134607788 cites W2156756890 @default.
• W2134607788 cites W2157583512 @default.
• W2134607788 cites W2159726703 @default.
• W2134607788 cites W2161118302 @default.
• W2134607788 cites W2161558564 @default.
• W2134607788 cites W2171479134 @default.
• W2134607788 cites W2321410278 @default.
• W2134607788 cites W2325776490 @default.
• W2134607788 cites W2595176684 @default.
• W2134607788 cites W2777987555 @default.
• W2134607788 cites W4232719749 @default.
• W2134607788 cites W4248937293 @default.
• W2134607788 cites W4251663941 @default.
• W2134607788 doi "https://doi.org/10.1111/j.1525-1403.2010.00282.x" @default.
• W2134607788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21992827" @default.
• W2134607788 hasPublicationYear "2010" @default.
• W2134607788 type Work @default.
• W2134607788 sameAs 2134607788 @default.
• W2134607788 citedByCount "22" @default.
• W2134607788 countsByYear W21346077882012 @default.
• W2134607788 countsByYear W21346077882013 @default.
• W2134607788 countsByYear W21346077882014 @default.
• W2134607788 countsByYear W21346077882015 @default.
• W2134607788 countsByYear W21346077882016 @default.
• W2134607788 countsByYear W21346077882017 @default.
• W2134607788 countsByYear W21346077882018 @default.
• W2134607788 countsByYear W21346077882020 @default.
• W2134607788 countsByYear W21346077882022 @default.
• W2134607788 countsByYear W21346077882023 @default.
• W2134607788 crossrefType "journal-article" @default.
• W2134607788 hasAuthorship W2134607788A5067081068 @default.
• W2134607788 hasAuthorship W2134607788A5083610914 @default.
• W2134607788 hasConcept C126322002 @default.
• W2134607788 hasConcept C142724271 @default.
• W2134607788 hasConcept C15744967 @default.
• W2134607788 hasConcept C169760540 @default.
• W2134607788 hasConcept C24998067 @default.
• W2134607788 hasConcept C25498285 @default.
• W2134607788 hasConcept C2777319143 @default.
• W2134607788 hasConcept C2778542668 @default.
• W2134607788 hasConcept C2779134260 @default.
• W2134607788 hasConcept C2779734285 @default.
• W2134607788 hasConcept C2780375056 @default.
• W2134607788 hasConcept C535046627 @default.
• W2134607788 hasConcept C71924100 @default.
• W2134607788 hasConcept C98274493 @default.

• next